CN1666980A - L-chelated calcium arginine - Google Patents
L-chelated calcium arginine Download PDFInfo
- Publication number
- CN1666980A CN1666980A CN 200410016922 CN200410016922A CN1666980A CN 1666980 A CN1666980 A CN 1666980A CN 200410016922 CN200410016922 CN 200410016922 CN 200410016922 A CN200410016922 A CN 200410016922A CN 1666980 A CN1666980 A CN 1666980A
- Authority
- CN
- China
- Prior art keywords
- calcium
- arginine
- people
- chelate
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011575 calcium Substances 0.000 title claims abstract description 45
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 35
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 239000004475 Arginine Substances 0.000 title abstract description 20
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title abstract description 20
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 8
- 229930064664 L-arginine Natural products 0.000 claims abstract description 7
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 239000013522 chelant Substances 0.000 claims description 11
- 235000018102 proteins Nutrition 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 239000000470 constituent Substances 0.000 claims description 6
- 235000009697 arginine Nutrition 0.000 abstract description 19
- 239000000126 substance Substances 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 230000035790 physiological processes and functions Effects 0.000 abstract description 3
- 239000002574 poison Substances 0.000 abstract description 2
- 231100000614 poison Toxicity 0.000 abstract description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- 238000010170 biological method Methods 0.000 abstract 1
- 230000003862 health status Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 206010006956 Calcium deficiency Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940106635 calcium amino acid chelate Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000018528 secretion by tissue Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention provides a new molecule belongs to soft calcium quality in soft matter. L-arginine chelating calcium made through chemical biological method, it can supply the needed calcium and arginine to living body. It can be used to protect several kinds of diseases bring by calcium lack and arginine lack and can make people in inferior-health status to recover to health status. Comparing to the calcium supply product now, it is easy to dissolve and absorb, pure and safety of its quality and no poison effect. It is a new substance that more accord with people's physiological function need and matching with people's bioenergy conversion. The figure is its formula.
Description
Technical field
The invention belongs to recruit's structure of biological medicine field of health care products, be particularly related to a kind of recruit and be the L-L-Argininum Ca of Chelate, this invention comes true the design design that the L-arginine combines with calcium constituent, and novel substance can change the actual state that metallic element calcium is difficult for being absorbed by the body; The recruit L-L-Argininum Ca of Chelate that forms can replenish the nutrition of necessary arginine of organism and calcium and treat and prevent various diseases, also can adjust the sub-health state of human body.
Background technology
Calcium also plays an active part in the metabolism of whole life except that the running balance of keeping skeletal calcium, from beating of the solidifying of the contraction of muscle, blood, neural conduction, heart elbow etc., all closely related to the growing of human body, disease, aging.
Along with Biomedical Development, calcium is familiar with gradually to the importance of life.Biological calcium deficiency, the human body calcium deficiency, women and children's calcium deficiency is even more serious.The whole nation Ministry of Health's announcement in 95 years spells out among the nutrition survey result for the third time: " among the mineral substance; the absorption of calcium significantly lacks; be supply standard (RAD) 50%, Chinese children rickets pilosity, elderly woman osteoporosis are punished severely, and be relevant with the calcium insufficiency of intake." calcium product is also a lot, but key is difficult for being absorbed by health mostly.
Summary of the invention
The present invention is the shortcoming that overcomes existing most of physical products, and a kind of soft calcareous amino acid calcium that is called is provided, the L-L-Argininum Ca of Chelate, and its structural formula is:
Molecular formula: C
12H
26N
8CaO
4
Molecular weight: 386.4686 (according to relative atomic weight meters in 1989)
English name: L-Argininum Ca of Chelate
Biological chemistry specific name: little peptide calcium, calcium amino acid chelate, L-Argininum Ca of Chelate
Arginine is a kind of basic aminoacids, is important condition amino acid.Though concerning the adult, be not must amino acid, in some situation such as body development is immature or under stressed condition, if lack arginine, just body can not be kept positive nitrogen balance and normal physiological function.Arginine is an integral part in the urea cycle, has extremely important physiological function.Eat arginine more, can increase the activity of arginase in the liver, help the ammonia in the blood to be converted into urea and to excrete.Arginic important metabolic function is the healing effect that promotes wound, can promote the synthetic of collagenous tissue.
Arginine can prevent the degeneration of thymus gland, and additional arginine can increase the weight of thymus gland, promotes the growth of thymus gland medium size lymphocyte.Arginine can promote the ripe and differentiation of CD cell in bone and the lymphoglandula.In immunity system, except that lymphocyte, cytophagous vigor is also relevant with arginine.After adding arginine, can activate its enzyme system, making it more can the kill tumor cell or target cell such as bacterium.
Arginine can stimulate the high glucemia element of Regular Insulin, pancreas in hypophysis secretion tethelin, prolactin and the pancreas, and these hormones have effect to promoting growth, and is relevant with the intravital immunologic function of raising again simultaneously.Arginine is the prerequisite material of synthetic polyamine, and polyamines is that the lymphocyte breeding is essential with growth.Arginine also is the necessary composition in the enzymes metabolism approach of NO and citrulline reaction.It can stimulate these organs and tissue secretion hormone, plays the effect of immunologic function.
The arginine safety non-toxic can be used the therapeutic dose of 0.5/kg (body weight) clinically.So, use arginine to innovate optimization as the carrier of calcium, be perfect composite design.
The present invention is set in the micromolecular category of little peptide, and promptly Zui Xiao albumen dipeptides claims little peptide again, and molecular weight is 386.4686, and little peptide is to assemble synthetic under the particular environment with amino acid outside organism, and calcium constituent also assembling simultaneously gets on.According to soft matter theory and Biological Principles, the hard material that will exist in the world originally in organism external application specific method divides the system combination again, be combined into directly adaptable soft material form of life entity, promptly change the not good essence of its original organism assimilation effect, and show the certain effects of design in advance.
The present invention does not relate to the quality of biological gene substantially, gene template is when carrying out the life assemblage of aminoacid sequence, this process also is accompanied by the transmittance process and the switching process of energy simultaneously, little peptide small molecules of the present invention provides and quickens the material (power) of this transmittance process and switching process, its basic theory is to talk acquired disposition on the basis of molecular genetics (gene transmission) and molecular epidemiology (genetic flaw) inborn factor, because the environment of the existence of life and its own existence has very important interaction, be what and the quality of quality that nutrient substance provides energy, equally vital process has been played very important influence, the possibility that transgenation may also be arranged of improvement of genes has promptly been arranged.Disease is the spontaneous phenomenon of vital process with failing naturally, and the present invention not only can treat the process that the disease that has occurred can delay the nature deterioration process again, and the generation of prevention some diseases in this process, really accomplishes good health and a long life.
Product of the present invention should be returned in product the 4th class of replenishing the calcium: L-L-Argininum Ca of Chelate, two amino acid of reason form minimum protein and show that it is active essential, so also can be described as little peptide in conjunction with calcium, with the material class discrimination, are called soft calcareous.
Calcium product original and newly developed on the market is a lot, but L-Argininum Ca of Chelate has its distinctive feature as the domestic new variety of replenishing the calcium, and it is made up of two parts: calcium constituent and arginine.If with regard to simple calcium product, the mechanism of replenishing the calcium is all identical, but the effect that different carriers produces is then different fully.The present invention is a carrier with two L-arginine, and two L-arginine have formed the little peptide that is similar to two natural peptide protein calcium with calcium constituent and combined calcium.The selection reason of carrier is, amino acid is the proteinic minimum unit that forms, and it is the basic substance of life.The gene relevant with heredity in fact also is the amino acid chain of different order.At present, relevant with human body 28 seed amino acids that have.The peptide chain that this 28 seed amino acid is arranged in the different order different lengths is formed the functional protein of body portion.Have 100 multiple proteins according to statistics.Protein in the meals does not directly constitute the protein in the health, but through after digesting and assimilating, mainly is transformed into amino acid in liver, and these amino acid are reassembled into intravital 100 multiple proteins again according to the needs of human body.Therefore, not protein and amino acid is only the nutrient substance that needed by human body is wanted strictly speaking.Amino acid can also be worked in coordination with the normal function that VITAMIN and mineral substance are kept body except the base substance as synthetic protein.
The present invention has selected the L-arginine for use, and the L-arginine can increase immunity of organisms, quickens microcirculation, promotes metabolism.Lack arginine and can cause poor growth, immunity degradation.Select this seed amino acid to form new molecule, can satisfy the not demand of preventing and treating of same-action, different ages, various disease substantially with combining of calcium constituent.The characteristics that the present invention has CL, easily absorbs, more meeting human-body biological can change and physiological requirements.
Embodiment
The present invention adopts preparation method's preparation of autonomous patent of invention technology (patent No. ZL96116524.3).
Structural formula of the present invention is:
Molecular formula: C
12H
26N
8ZnO
4
Molecular weight: 411.7686 (according to relative atomic weight meters in 1989)
Can make tablet, hard capsule, soft capsule, micro-capsule, granule, oral liquid, injection etc. with it during concrete the use; Also can be made into the obedient agent of external application etc.
Product proterties of the present invention: this product is the finely powdered white particle, and odorless is little puckery, soluble in water, is insoluble to organic solvents such as ethanol, ether substantially, has water absorbability.Products characteristics of the present invention: dissolve, good absorption has good calcium supplementing effect, and improves the organism fatigue state, more meets the bioenergy conversion and the physiological requirements of human body.
Product mechanism of action of the present invention: the L-Calcium 2-amino-5-guanidinovalerate is a kind of stable water-soluble chelate structure, the essence of little peptide binding substances, oral post-absorption is good, can't combine with oxalic acid, the phytic acid in the food and influence absorption, absorpting form with little peptide ammino acid in small intestine is entered in the body by abundant the absorption, do not need to add Vitamin D3 500,000 I.U/GM and promote to absorb, the danger of having avoided D3 to poison.
Indication of the present invention: recovery, infantile osteomalacia, the promotion that is used for osteoporosis, fracture grown, infertility, sexual disorder, malnutrition, postoperative wound healing etc.; And can be used for the assisting therapy of hypertension, diabetes, meningitic sequela, senile dementia etc.; Also be applicable to disease aid nutrition such as regulating the chronic persistent hepatitis immune, that immunity degradation causes, chronic nephritis; And especially the prevention and health care and the sub-health state of adult man there is special efficacy.
Claims (2)
1, a kind of L-L-Argininum Ca of Chelate, the recruit shows following feature:
(1) structural formula is:
(2) molecular formula: C
12H
26N
8CaO
4
(3) molecular weight: 386.4686
2, L-L-Argininum Ca of Chelate according to claim 1; It is characterized in that two L-arginine have formed the little peptide that is similar to two natural peptide protein calcium with calcium constituent and combined calcium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410016922 CN1666980A (en) | 2004-03-12 | 2004-03-12 | L-chelated calcium arginine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410016922 CN1666980A (en) | 2004-03-12 | 2004-03-12 | L-chelated calcium arginine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1666980A true CN1666980A (en) | 2005-09-14 |
Family
ID=35038289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410016922 Pending CN1666980A (en) | 2004-03-12 | 2004-03-12 | L-chelated calcium arginine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1666980A (en) |
-
2004
- 2004-03-12 CN CN 200410016922 patent/CN1666980A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100502692C (en) | A kind of physical recovery health food and preparation method thereof | |
| TW200848064A (en) | Process for producing osteocalcin-containing extract | |
| CN107164446A (en) | The preparation method and its antifatigue effect of deer hemepeptide | |
| JP2002034592A (en) | Method for producing protein-zinc readily absorbable in body | |
| CN1535605A (en) | Drink and food | |
| CA2514687A1 (en) | Advenced vitamin c-based composition with enhanced biotransformation and utilization of protein and l-carnitine for nutritional supplementation or the like | |
| CN110384134A (en) | A kind of compound tree peony seed oil polypeptide soft capsule | |
| CN101062025A (en) | Compound preparation for weight loss, fat reduction, blood sugar reduction, blood pressure reduction, and prevention and treatment of osteoporosis | |
| CN1101700C (en) | Polypeptide oral liquor | |
| AU9401998A (en) | Fatty acids as a diet supplement | |
| CN1170587C (en) | I (Robinia Pseudoacacia) lectin and its uses | |
| CN103330118A (en) | Antiobesity drug | |
| RU2134522C1 (en) | Biologically active food additive from laminaria | |
| CN1666980A (en) | L-chelated calcium arginine | |
| CN1066485C (en) | Peptide-containing protein wine | |
| CN1238487C (en) | Process for producing deer-blood wine | |
| CN1292756C (en) | Effervescence tablet preparation for replenishing nutritious elements to human being and its preparation method | |
| CN1666976A (en) | L-chelated zinc arginine | |
| CN1666978A (en) | L-chelated calcium lysine | |
| CN1467198A (en) | Monozinc di-L-Aspartate | |
| CN101057856A (en) | Fast recovery agent for seeding vitality used in aquiculture | |
| CN1666977A (en) | L-chelated magnesium arginine | |
| CN108991358A (en) | A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food and production method | |
| CN1122714C (en) | High calcium vinegar | |
| CN108936600A (en) | A method of the rouge ferment that disappears is prepared using brown rice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |